Hoban D J, Koss J C, Gratton C A, Ronald A R
J Clin Microbiol. 1983 Jun;17(6):1061-5. doi: 10.1128/jcm.17.6.1061-1065.1983.
A study was undertaken to evaluate the effectiveness of the MS-2 (Abbott Laboratories, Dallas, Tex.) in screening urine specimens in a large clinical laboratory. A total of 15,319 urine specimens (9,954 midstream specimens and 5,365 catheter specimens) were evaluated with the MS-2 and by a surface streak procedure. The study was conducted in two phases, differing in that phase II urine specimens were evaluated in the MS-2 by using a program software update (03.01). For midstream urine specimens, MS-2 detection rates in phases I and II were, respectively, 94.5 and 94.3% at a plate count of greater than 10(5) CFU/ml, 74.4 and 65.3% at plate counts of 5 X 10(4) to 1 X 10(5) CFU/ml, 55.0 and 52.4% at plate counts of 1 X 10(4) to 5 X 10(4) CFU/ml, 31.2 and 20.5% at plate counts of 10(3) to 10(4) CFU/ml, and 15.7 and 6.4% at plate counts of less than 10(3) CFU/ml. For catheter urine specimens, the MS-2 detection rates in phases I and II were, respectively, 95.4 and 96.8% at plate counts greater than 10(5) CFU/ml, 74.4 and 85.7% at plate counts of 5 X 10(4) to 1 X 10(5) CFU/ml, 50.0 and 44.4% at plate counts 10(4) to 5 X 10(4) CFU/ml, 25.6 and 14.9% at plate counts of 10(3) to 10(4) CFU/ml, and 14.7 and 5.2% at plate counts less than 10(3) CFU/ml.
开展了一项研究，以评估MS - 2（雅培实验室，得克萨斯州达拉斯）在一家大型临床实验室筛查尿液标本的有效性。总共15319份尿液标本（9954份中段尿标本和5365份导尿管尿标本）通过MS - 2并采用表面划线法进行了评估。该研究分两个阶段进行，不同之处在于，第二阶段的尿液标本在MS - 2中通过使用程序软件更新（03.01）进行评估。对于中段尿标本，第一阶段和第二阶段的MS - 2检测率分别为：平板计数大于10⁵CFU/ml时为94.5%和94.3%；平板计数为5×10⁴至1×10⁵CFU/ml时为74.4%和65.3%；平板计数为1×10⁴至5×10⁴CFU/ml时为55.0%和52.4%；平板计数为10³至10⁴CFU/ml时为31.2%和20.5%；平板计数小于10³CFU/ml时为15.7%和6.4%。对于导尿管尿标本，第一阶段和第二阶段的MS - 2检测率分别为：平板计数大于10⁵CFU/ml时为95.4%和96.8%；平板计数为5×10⁴至1×10⁵CFU/ml时为74.4%和85.7%；平板计数为10⁴至5×10⁴CFU/ml时为50.0%和44.4%；平板计数为10³至10⁴CFU/ml时为25.6%和14.9%；平板计数小于10³CFU/ml时为14.7%和5.2%。
